Genfit S.A. (EPA:GNFT)

Market Cap	166.02M
Revenue (ttm)	70.69M
Net Income (ttm)	1.51M
Shares Out	49.80M
EPS (ttm)	0.03
PE Ratio	111.13
Forward PE	1.90
Dividend	n/a
Ex-Dividend Date	n/a

Volume	62,186
Average Volume	126,883
Open	3.344
Previous Close	3.334
Day's Range	3.344 - 3.386
52-Week Range	2.620 - 5.860
Beta	1.27
RSI	35.49
Earnings Date	Sep 22, 2025

About Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patien...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 180
• Stock Exchange: Euronext Paris
• Ticker Symbol: GNFT